SISTER–Subcutaneous: Non-interventional, observational, prospective, German multicenter, open label study over 12 months for Tysabri Patient Preference Experience from Real World –Preliminary results of the 1stinterim analysis

28. októbra 2022 4 videnia
Gold R et al.

Skrátená informácia o lieku

tysabri avonex tecfidera fampyra plegridy
2012 - 2024 Copyright Farmi-Profi, spol. s r.o - Všetky práva vyhradené - Made by Elite ML